XDx's AlloMap Heart-Rejection Test Racks Up Payor Wins, But Walls Remain

The decision by Blue Shield of California to cover the assay, which extends to more than one year post-transplant, means most stable heart-transplant recipients on its rolls won't have to undergo organ-function biopsies.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

The XDx story captures in a

The XDx story captures in a nutshell why our healthcare is so expensive. When the incentives for ripping out bits of a patient's heart are more compelling to doctors than those for a simple blood test, something is wrong. I question why an insurer that looked at the evidence and approved the XDx assay would continue to pay for the much more risky biopsy.